Publication:
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals

Simple item page
dc.contributor.authorLozano-Ojalvo, Daniel
dc.contributor.authorCamara, Carmen
dc.contributor.authorLopez-Granados, Eduardo
dc.contributor.authorNozal, Pilar
dc.contributor.authorDel Pino-Molina, Lucía
dc.contributor.authorBravo-Gallego, Luz Yadira
dc.contributor.authorPaz-Artal, Estela
dc.contributor.authorPion, Marjorie
dc.contributor.authorCorrea-Rocha, Rafael
dc.contributor.authorOrtiz, Alberto
dc.contributor.authorLopez-Hoyos, Marcos
dc.contributor.authorIribarren, Marta Erro
dc.contributor.authorPortoles, Jose
dc.contributor.authorRojo-Portoles, Maria Pilar
dc.contributor.authorOjeda, Gloria
dc.contributor.authorCervera Hernandez, Isabel
dc.contributor.authorGonzalez-Perez, Maria
dc.contributor.authorBodega-Mayor, Irene
dc.contributor.authorMontes-Casado, Maria
dc.contributor.authorPortoles, Pilar
dc.contributor.authorPerez-Olmeda, Mayte
dc.contributor.authorOteo-Iglesias, Jesus
dc.contributor.authorSanchez-Tarjuelo, Rodrigo
dc.contributor.authorPothula, Venu
dc.contributor.authorSchwarz, Megan
dc.contributor.authorBrahmachary, Manisha
dc.contributor.authorTan, Anthony Tanoto
dc.contributor.authorLe Bert, Nina
dc.contributor.authorBerin, Cecilia
dc.contributor.authorBertoletti, Antonio
dc.contributor.authorGuccione, Ernesto
dc.contributor.authorOchando, Jordi
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderNIH - National Cancer Institute (NCI) (Estados Unidos)
dc.contributor.funderIcahn School of Medicine at Mount Sinai
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderGobierno de Cantabria (España)
dc.contributor.funderUnión Europea. Comisión Europea. H2020
dc.contributor.funderNational Institutes of Health (Estados Unidos)
dc.date.accessioned2022-04-25T11:18:51Z
dc.date.available2022-04-25T11:18:51Z
dc.date.issued2021-08-24
dc.description.abstractThe rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipResearch reported in this publication was supported in part by the National Cancer Institute of the NIH (5R01HD102614-02; R01CA249204 and R01CA248984) and an ISMMS seed fund to E.G. The authors gratefully acknowledge use of the services and facilities of the Tisch Cancer Institute supported by a NCI Cancer Center Support Grant (P30 CA196521). M.S. was supported by a NCI training grant (T32CA078207). This work was supported by an ISMMS seed fund to J.O.; Instituto de Salud Carlos III (COV20-00668) to R.C.R.; the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 research call COV20/00181) co-financed by the European Development Regional Fund “A way to achieve Europe” to E.P.; the Instituto de Salud Carlos III, Spain (COV20/00170); the Government of Cantabria, Spain (2020UIC22-PUB-0019) to M.L.H.; the Instituto de Salud Carlos III (PI16CIII/00012) to P.P.; the Fondo Social Europeo e Iniciativa de Empleo Juvenil YEI (Grant PEJ2018-004557-A) to M.P.E.; and by REDInREN 016/009/009 ISCIII. This project has received funding from the European Union Horizon 2020 research and innovation programs VACCELERATE and INsTRuCT under grant agreements 101037867 and 860003.es_ES
dc.format.number8es_ES
dc.format.page109570es_ES
dc.format.volume36es_ES
dc.identifier.citationCell Rep. 2021;36(8):109570.es_ES
dc.identifier.doi10.1016/j.celrep.2021.109570es_ES
dc.identifier.e-issn2211-1247es_ES
dc.identifier.journalCell Reportses_ES
dc.identifier.pubmedID34390647es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14165
dc.language.isoenges_ES
dc.publisherCell Press
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20-00668es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20/00181es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI16CIII/00012es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PEJ2018-004557-Aes_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/REDInREN 016/009/009es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/101037867/EUes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/860003/EUes_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.celrep.2021.109570es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectBNT162b2 vaccinees_ES
dc.subjectCOVID-19es_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectT-cell immunityes_ES
dc.titleDifferential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individualses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication1e8a3e4e-f09a-4171-94fa-72a3021cc568
relation.isAuthorOfPublicationa1ded7fc-43c9-4dae-af2c-a61061e07643
relation.isAuthorOfPublication61c96268-73e7-4a41-a915-896ef6b3a080
relation.isAuthorOfPublication6056fa39-01b3-4fda-bc24-419aa4f54ccc
relation.isAuthorOfPublication0a4ee614-8ec2-4341-bff7-499105644a44
relation.isAuthorOfPublicatione71de9b6-237d-43da-87fa-fd8842500b96
relation.isAuthorOfPublicationd01866d4-34ba-4cd6-b995-3c4199bf0c59
relation.isAuthorOfPublication4ac67376-8b3e-48bd-9415-8770421fdd67
relation.isAuthorOfPublication6a7d9ff1-3a69-4fa2-a1c6-6f1a3ab06dfe
relation.isAuthorOfPublicationf4411902-c52c-4e77-afff-0f9d9e8d9e9f
relation.isAuthorOfPublication.latestForDiscovery1e8a3e4e-f09a-4171-94fa-72a3021cc568
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublicationb589134c-ce3e-4f64-a3f5-83d0a7eb706a
relation.isFunderOfPublication807f2e10-40be-4596-9cc4-810653947f6d
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication2151ccc5-a8a0-4344-bb28-e39e74602b7c
relation.isFunderOfPublicationa418cf3b-f427-4376-a75f-01dba9bb944f
relation.isFunderOfPublicationd863b318-3e6b-4cfc-81bb-a6d112b1f86e
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublicationaea619d1-42a6-47f8-84e2-6bc27d6f8300
relation.isPublisherOfPublication.latestForDiscoveryaea619d1-42a6-47f8-84e2-6bc27d6f8300

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
DifferentialEffectsOfThe_2021.pdf
Size:
1.77 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Centro Nacional de Microbiología (CNM)
i+12 - Instituto de Investigación Hospital 12 de Octubre (Madrid)
IdiPAZ - Instituto de Investigación Sanitaria Hospital La Paz (Madrid)
IDIVAL - Instituto de Investigación Marqués de Valdecilla (Cantabria)
IIS-FJD - Instituto de Investigación Sanitaria Fundación Jiménez Díaz (Madrid)
IiSGM - Instituto de Investigación Sanitaria Gregorio Marañón (Madrid)